ENZN - Enzon Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.29
+0.02 (+8.61%)
At close: 3:03PM EDT
Stock chart is not supported by your current browser
Previous Close0.27
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume72,878
Market Cap12.82M
Beta0.18
PE Ratio (TTM)14.50
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2015-12-30
1y Target EstN/A
Trade prices are not sourced from all markets
  • Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
    Capital Cube20 days ago

    Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017

    Categories: Yahoo FinanceGet free summary analysis Enzon Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 6.78 million, Net Earnings of USD 4.19 million. Change in operating cash flow of 109.02% compared to same period last year is about the same as change in earnings, likely no significant ... Read more (Read more...)

  • Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017
    Capital Cube5 months ago

    Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017

    Categories: Yahoo FinanceGet free summary analysis Enzon Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Enzon Pharmaceuticals, Inc. – Nektar Therapeutics, Amgen Inc., Enanta Pharmaceuticals, Inc., Pfizer Inc., Merck & Co., Inc., Valeant Pharmaceuticals International Inc, XOMA Corporation, SciClone Pharmaceuticals, Inc., Gilead Sciences, ... Read more (Read more...)

  • Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017
    Capital Cube7 months ago

    Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017

    Categories: Yahoo Finance Get free summary analysis Enzon Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Enzon Pharmaceuticals, Inc. – Nektar Therapeutics, Amgen Inc., Enanta Pharmaceuticals, Inc., Pfizer Inc., Merck & Co., Inc., Valeant Pharmaceuticals International Inc, XOMA Corporation, SciClone Pharmaceuticals, Inc. and Gilead ... Read more (Read more...)

  • Carl Icahn Takes 15% Stake in Enzon Pharmaceuticals
    GuruFocus.com11 months ago

    Carl Icahn Takes 15% Stake in Enzon Pharmaceuticals

    Activist investor continues his interest in penny stock

  • Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016
    Capital Cube11 months ago

    Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016

    Categories: Yahoo Finance Get free summary analysis Enzon Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Enzon Pharmaceuticals, Inc. – Nektar Therapeutics, Amgen Inc., Merck & Co., Inc., XOMA Corporation, Bristol-Myers Squibb Company, Pfizer Inc., SciClone Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated and Gilead Sciences, ... Read more (Read more...)